Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT02989584 trial: what clinicians have said so far
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
- NCT02989584 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02989584 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02989584 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer; Metastatic Bladder Cancer; Urothelial Carcinoma
- Interventions
- Atezolizumab; Gemcitabine; Cisplatin
- Arms
- Atezolizumab, Gemcitabine, Cisplatin · Experimental
- Enrollment
- 54
- Primary outcomes
- Test the safety of atezolizumab in combination with gemcitabine/cisplatin as assessed by dose limiting toxicity rate.
- Sponsor
- Memorial Sloan Kettering Cancer Center with Genentech, Inc.
- Start
- Dec 20, 2016
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02989584 · updated Oct 26, 2026
Publications
linked from the registry- Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28. PubMed 35089812